Nutra Pharma Corp. Announces Nyloxin Television Commercial Rollout

CORAL SPRINGS, FL--(Marketwired - June 25, 2014) - Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a company that has the exclusive rights to market and distribute Nutra Pharma’s over-the-counter (OTC) pain reliever, Nyloxin®, has begun airing television commercials as of Monday, June 23rd. The advertisements focus on the benefits of Nyloxin®. The first contract has already begun and includes over 30,000 spots to run throughout the Southeast Region from Comcast and AT&T U-Verse Cable providers. The ads are scheduled to run on the following channels: GOLF, LMN, CNBC, FOXN, MSNBC, NBCS, ESPN, ESPN2, TNT, FOXS, TWC, CNN, HALL, HGTV, TLC, HLN and LIFE. Starting June 30, the commercials will begin airing in the New York and New Jersey markets with a rollout to the national stage in the coming weeks.

“MyNyloxin is extremely pleased to get these commercials aired,” stated Dalton Johnson, CEO of MyNyloxin.com. “The initial rollout has begun throughout the South Florida market and we’ve already seen incremental sales growth,” he continued. “We believe that these advertisements will capture the imagination of potential customers that need access to a superior pain relief product and should help grow sales in the short term,” he concluded.

Nyloxin® is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin® is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin® is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.

“MyNyloxin Distributors have been steadily increasing the public awareness of Nyloxin,” said Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “They have consistently met their targets with the launch of these commercials this week as scheduled,” he continued. “We have seen the beginning of the sales being driven by this advertising campaign and expect steady gains with the eventual rollout to the national stage over the next several weeks,” he concluded.

The commercials can be viewed online at: http://tinyurl.com/NyloxinAds

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brands Cobroxin® and Nyloxin®. For additional information about Nutra Pharma, visit:
http://www.NutraPharma.com or
http://www.Nyloxin.com.

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases “would be,” “will allow,” “intends to,” “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimate,” “project,” or similar expressions are intended to identify “forward-looking statements.” Actual results could differ materially from those projected in Nutra Pharma’s (“the Company”) business plan. The rollout of the Nyloxin commercials should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company’s filings may be accessed at the SEC’s Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.